Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

Last Close
Feb 23 04:00PM ET
Dollar change
Percentage change
IndexRUT P/E- EPS (ttm)-1.16 Insider Own8.04% Shs Outstand41.49M Perf Week-0.75%
Market Cap275.08M Forward P/E- EPS next Y-1.04 Insider Trans0.65% Shs Float38.15M Perf Month15.51%
Income-39.92M PEG- EPS next Q-0.28 Inst Own30.92% Short Float5.58% Perf Quarter47.01%
Sales16.56M P/S16.61 EPS this Y0.17% Inst Trans-5.59% Short Ratio7.97 Perf Half Y31.81%
Book/sh1.86 P/B3.56 EPS next Y13.19% ROA-30.88% Short Interest2.13M Perf Year17.76%
Cash/sh3.02 P/C2.19 EPS next 5Y- ROE-49.51% 52W Range3.89 - 7.28 Perf YTD1.22%
Dividend Est.- P/FCF- EPS past 5Y52.02% ROI-35.68% 52W High-8.93% Beta1.82
Dividend TTM- Quick Ratio6.31 Sales past 5Y13.90% Gross Margin90.29% 52W Low70.44% ATR (14)0.34
Dividend Ex-Date- Current Ratio6.31 EPS Y/Y TTM-13.35% Oper. Margin-266.78% RSI (14)60.09 Volatility6.12% 5.07%
Employees36 Debt/Eq0.66 Sales Y/Y TTM54.49% Profit Margin-241.00% Recom1.00 Target Price18.25
Option/ShortYes / Yes LT Debt/Eq0.66 EPS Q/Q-110.90% Payout- Rel Volume0.65 Prev Close6.80
Sales Surprise-14.33% EPS Surprise-34.45% Sales Q/Q0.73% EarningsNov 07 BMO Avg Volume266.94K Price6.63
SMA207.73% SMA5013.97% SMA20029.01% Trades Volume173,670 Change-2.50%
Date Action Analyst Rating Change Price Target Change
Mar-17-23Initiated Maxim Group Buy $12
Feb-15-24 03:49AM
Feb-06-24 07:30AM
Jan-23-24 07:30AM
Jan-08-24 07:30AM
Jan-04-24 08:55AM
07:30AM Loading…
Dec-27-23 07:30AM
Nov-20-23 07:30AM
Nov-12-23 08:42AM
Nov-07-23 08:17AM
Oct-31-23 07:30AM
Oct-19-23 07:30AM
Oct-10-23 07:30AM
Oct-05-23 07:30AM
07:30AM Loading…
Oct-02-23 07:30AM
Sep-20-23 07:30AM
Sep-09-23 08:00PM
Sep-05-23 07:30AM
Sep-04-23 09:55AM
Sep-01-23 07:31AM
Aug-31-23 12:13PM
Aug-19-23 07:40AM
Aug-17-23 09:55AM
Aug-15-23 12:15AM
Aug-14-23 07:42AM
Aug-07-23 04:45PM
Aug-02-23 07:30AM
10:30AM Loading…
Jul-19-23 10:30AM
Jun-20-23 07:30AM
Jun-13-23 07:30AM
Jun-03-23 07:30AM
May-16-23 06:22AM
May-15-23 05:55PM
May-10-23 07:30AM
May-09-23 07:30AM
May-08-23 07:30AM
May-03-23 07:30AM
Apr-17-23 04:05PM
Apr-04-23 07:30AM
Mar-30-23 07:30AM
Mar-17-23 07:30AM
Mar-15-23 07:26AM
Mar-07-23 07:00AM
Mar-06-23 07:30AM
Zevra Therapeutics, Inc. is a clinical-stage specialty pharmaceutical company, which engages in the discovery and development of proprietary prodrugs. It focuses on the treatment of serious medical conditions such as attention deficit hyperactivity disorder, pain, and other central nervous system disorders through its platform technology known as Ligand Activated Therapy. The company was founded by Christal M. M. Mickle and Travis C. Mickle on October 30, 2006 and is headquartered in Celebration, FL.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Anderson ThomasDirectorSep 06Buy4.8810,00048,76410,000Sep 06 04:39 PM
Clifton R. LaDuaneCFO, Secretary & TreasurerSep 06Buy4.961,0004,95915,309Sep 06 05:11 PM
Bode John BDirectorSep 05Buy5.1310,00051,33320,000Sep 06 04:40 PM
Schafer JoshuaCCO & EVP, Bus. DevelopmentSep 05Buy5.135002,5643,500Sep 06 05:11 PM
Watton Corey MichaelDirectorJun 23Buy5.952751,6361,000Jun 26 04:19 PM
Watton Corey MichaelDirectorJun 09Buy5.523251,794725Jun 13 08:35 PM
Watton Corey MichaelDirectorMay 30Buy5.114002,042400May 31 11:34 AM
Schafer JoshuaCCO & EVP, Bus. DevelopmentMay 19Buy5.421,0005,4163,000Jun 30 04:14 PM
Bode John BDirectorMay 18Buy5.0410,00050,41810,000May 19 05:53 PM
Clifton R. LaDuaneCFO, Secretary & TreasurerMay 18Buy4.952,74013,56213,742May 18 04:56 PM
SEYMOUR TAMARA ADirectorMar 17Buy4.825192,502719Mar 21 04:32 PM
Schafer JoshuaCCO & EVP, Bus. DevelopmentMar 14Buy4.612,0009,2182,000Mar 15 08:14 PM
Clifton R. LaDuaneCFO, Secretary & TreasurerMar 10Buy4.151,7257,15911,002Mar 13 07:56 AM
Sangiovanni Timothy J.SVP, Corporate ControllerMar 10Buy4.141,2004,9674,449Mar 13 07:57 AM
Plooster Matthew RDirectorMar 09Buy4.2011,00046,14818,500Mar 13 07:59 AM
Pascoe Richard WChief Executive OfficerMar 09Buy4.2010,00041,97829,973Mar 13 07:53 AM
Tierney David SDirectorMar 09Buy4.155,00020,73210,835Mar 13 07:54 AM